Amalgamated Financial’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Amalgamated Financial’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$66K	Buy	+4,078	New	+$63.9K	﹤0.01%	2291

Other funds holding ICPT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Amalgamated Financial's ICPT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2022: 4,078 shares worth $66K. The stake represents ﹤0.01% of the portfolio and ranks #2291 among its holdings.

148 funds tracked by Wall St. Rank hold ICPT as of Q1 2022.

Amalgamated Financial held 4,078 shares of Intercept Pharmaceuticals, Inc. worth $66K as of Q1 2022.
Intercept Pharmaceuticals, Inc. was a new Amalgamated Financial position in Q1 2022.
Intercept Pharmaceuticals, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2291 holding.
148 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.